Drugs & Targets Clairity becomes the first FDA-authorized AI platform for breast cancer prediction June 06, 2025Vol.51 No.22
Drugs & Targets EC approves Adcetris for newly diagnosed Hodgkin lymphoma in combination with ECADD June 06, 2025Vol.51 No.22
Drugs & Targets China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer June 06, 2025Vol.51 No.22
Drugs & Targets Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S. June 06, 2025Vol.51 No.22
Drugs & Targets FDA grants priority review for sevabertinib in HER2-mutant NSCLC May 30, 2025Vol.51 No.21
Drugs & Targets Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer May 30, 2025Vol.51 No.21
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer May 23, 2025Vol.51 No.20
Drugs & Targets FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression May 16, 2025Vol.51 No.19
Drugs & Targets RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center May 16, 2025Vol.51 No.19
